Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA...
Transcript of Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA...
![Page 1: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/1.jpg)
www.mghcme.org
Novel Treatments for Mood DisordersMichael E. Henry, MD
Medical Director Bipolar Clinic and Research Program
Director Somatic Therapy
Massachusetts General Hospital
![Page 2: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/2.jpg)
www.mghcme.org
Disclosures
My spouse/partner and I have the following relevant financial relationship with a commercial
interest to disclose: Spouse is an employee of Roche
Pharmaceuticals
![Page 3: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/3.jpg)
www.mghcme.org
MDD Statistics
• 12 month prevalence U.S.: 9%• Mortality from Suicide: 20+ x gen pop• Increased risk of CV death.• Economic Costs to U.S: $36.6 Billion
Lepine JP, Briley M. Neuropsychiatr Dis Treat 2011; 7(suppl 1) 3-7.
![Page 4: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/4.jpg)
www.mghcme.org
Depression Model
Adapted from Mayberg, 2003
![Page 5: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/5.jpg)
www.mghcme.org
Targets
• Glutamate• GABA• Monoamines• Opiates• Inflammation• Neurosteroids• Mood Stabilizers• Neuromodulation• Non-Pharmacologic Tools
![Page 6: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/6.jpg)
www.mghcme.org
Glutamate Synapse
![Page 7: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/7.jpg)
www.mghcme.org
Glutamate
• NMDA• AMPA• Metabotropic • Allosteric Modulators• EAAT augmentation
![Page 8: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/8.jpg)
www.mghcme.org
NMDA
• R-Ketamine (PCN-101; HR071603)- Lower potency NMDAr antagonist (PCP site)- Lower potency DARI- Longer lasting AD effects in animal models. - Phase I trial underway in China
![Page 9: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/9.jpg)
www.mghcme.org
NMDA
BHV – 5000• “Low trapping” NMDA antagonist• Lanicemine – active metabolite• Phase II – CRPS • Plan MDD
![Page 10: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/10.jpg)
www.mghcme.org
Combination Medication
• AXS – 05- Buproprion/dextromethorphan- DM: NMDA and sigma-1 agonist, TRI,
Nicotinic receptor antagonist. - Breakthrough Therapy Designation for MDD,
AD agitation- Fast Track: TRD- Currently in phase III
![Page 11: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/11.jpg)
www.mghcme.org
AMPA• Perampanel – FDA approved anticonvulsant
- AMPA antagonist- 8 mg/d and 12 mg/d: 12 and 20% hostility AE- Probe for ketamine.
• Org 24448 – potentiates AMPA subfamily GLUR - Study was withdrawn
• Rapastinel- 2016 Breakthrough Therapy designation
from FDA- NR2B triggers influx of intracellular calcium- Increased AMPA - Phase III trials did not separate from placebo.
![Page 12: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/12.jpg)
www.mghcme.org
Metabotropic
• BCI-632- inhibits mGLU 2/3 presynaptic autoreceptor- Increases serotonin release - Chronic administration – hippocampalneurogenesis- “Ketamine without psychosis”
• BCI-838- Prodrug- Single and multiple escalating dose study
completed
![Page 13: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/13.jpg)
www.mghcme.org
EAAT
• Troriluzole BHV-4157- Increases glial glutamate transporter-1
![Page 14: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/14.jpg)
www.mghcme.orgCaprioli D et al.,2017 Biol Psych
![Page 15: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/15.jpg)
www.mghcme.org
Allosteric Modulators of NMDA
• Positive- CAD-9303 – negative sx’s of Schizophrenia
• Negative- CAD-9271- Treatment Resistant Depression- NMDAr 2B selective negative allosteric
modulator- Currently in phase 2.
![Page 16: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/16.jpg)
www.mghcme.org
Glycine Modulators• AV-101
- Oral prodrug of 7-chloro-kynurenic acid- Potent glycine antagonist.- Fast-track status for adjunct treatment TRD- Phase II trials underway
![Page 17: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/17.jpg)
www.mghcme.org
Purine Antagonists
• JNJ-54175446-P2X7 receptor antagonist-Gene in area identified as susceptible to
mood disorders- Receptor highly expressed in microglia.
Mediates Glu release - IL-1β- Phase II trial ongoing (12/21).
Neuroscience and Behavioral Reviews, 2018:192-205
![Page 18: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/18.jpg)
www.mghcme.org
GABA Modulators
Alopregnanolone (Brexanolone)• GABA-A receptor agonist• Postpartum Depression• Metabolites antagonize NMDA• Men and Women with PTSD deficient
alloprenanolone.• Combined with extinction protocol.• Study completion expected 2025.
![Page 19: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/19.jpg)
www.mghcme.org
GABA Modulators
• Ganaxolone- GABA-A Allosteric modulator-hyperpolarizes- Phase II for status epileticus
• SAGE-217- GABA-A Allosteric modulator- Failed Phase III trial – suspended program
![Page 20: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/20.jpg)
www.mghcme.org
Monoamine Projections
Neurowiki2012 –MAO in depression
![Page 21: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/21.jpg)
www.mghcme.org
Hallucinogens
• 5-HT2A partial agonists• Metabotropic Serotonin Receptor agonists• PFC, Thalamus• Raphe nuclei• Three chemical classes
- Tryptamines- Lysergamines- Phenethylamines
• Psychotherapy augmentation
Baumeister D et al. Ther Adv Psychopharmacol 2014
![Page 22: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/22.jpg)
www.mghcme.org
Triple Reuptake Inhibitors(SNDRI’s)
• Ideal Profile: Strong SERT; intermediate NET; and mild DAT inhibition. S. Stahl 2013
• Cocaine• Phencyclidine• Ketamine• Ginkgo biloba extract (EGb761) Wikipedia 2017
![Page 23: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/23.jpg)
www.mghcme.org
SNDRI
Ansofaxine-Prodrug of desvenlafaxine-SERT:NET:DAT: 4:5:3 -NDA filed with FDA, March 2020.
![Page 24: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/24.jpg)
www.mghcme.org
SNDRI
Mazindol• IR previously marketed as obesity drug• 2 Sustained release preparations in
development• NE reuptake inhibitor • Blocks cocaine binding to DA receptors• Phase II for Narcolepsy and ADHD
![Page 25: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/25.jpg)
www.mghcme.org
Opiates and Monamines
Lutz PE, Kieffer BL., Trends Neurosci 2013; 195- 206
![Page 26: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/26.jpg)
www.mghcme.org
Opiate Receptors• Mu
- Increased GABA tone on 5-HT neurons• Kappa
- Agonists are potent analgesics- Dysphoria, hallucinations, dissociation- Antagonists reverse learned helplessness.- Dynophan: decreases Glu and DA- BDNF
• Delta- BDNF
• Opioid Receptor Like 1 (ORL1)
Dhir A. Expert Opinion on Investigational Drugs; 2016
![Page 27: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/27.jpg)
www.mghcme.org
Opiate Candidates
• Buprenorphine (MOR partial agonist; KOR antagonist)- Used off label for TRD
• ALKS-5461- buprenorphine/samidorphan- KOR antagonist- FDA rejected NDA.
![Page 28: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/28.jpg)
www.mghcme.org
Opiate Candidates
CERC - 501 • Short acting KOR antagonist. • 30 fold selectivity for k receptors relative to
mu and delta OR’s.• 2017 sold to Janssen - JNJ-67953964• Phase IIA trial completed May 6, 2020.
![Page 29: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/29.jpg)
www.mghcme.org
Inflammatory Cytokines
HPA Axis
BDNF Monoamine reuptake
IDO
Depression Adapted from Nekovarova T. et al., Front Behav Neurosci 2014; 8:99 epub
Inflammation and Depression
![Page 30: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/30.jpg)
www.mghcme.org
Inflammatory Markers and Depression
Meta Analysis 1967 - 2008• Interleukin-1
d=0.35 (95%CI:0.03-0.67) p=0.03• Interleukin-6
d=0.25 (95%CI:0.18-0.31) p<0.001• C-Reactive Protein
d=0.15 (95%CI:0.10-0.21) p<0.001Howren M, et al. Psychosomatic Medicine 2009; 71:171-186.
![Page 31: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/31.jpg)
www.mghcme.org
Inflammation
Infliximab• Tumor Necrosis Factor (TNF)• 4 studies, 152 subjects.• No Difference in HAM-D scores.• Elevated TNF, CRP may define treatment
responsive subtype. Bavaresco DV et al., Pharmacol Biochem Behav 2020
![Page 32: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/32.jpg)
www.mghcme.org
Inflammation
• Exercise/weight loss• Sertraline/ketoprofen – 2017
- Interleukin - Results pending
![Page 33: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/33.jpg)
www.mghcme.org
Inflammation
ALKS-3831• Olanzapine/Samidorphan
- MOR antagonist• NDA filed• Samidorphan mitigates weight gain associated
with olanzapine.
![Page 34: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/34.jpg)
www.mghcme.org
Neurosteroids
PH-10• MDD• Inhaled Neurosteroid• Phase IIA: 8 week trial • n=30; PBO, 3.2 ug, 6.4 ug• 8 week HAMD: 6.4 ug-17.8 vs PBO -10.9
p=0.02- 1 week HAMD: 6.4 ug-10.1 vs PBO -4.2
p=0.03
![Page 35: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/35.jpg)
www.mghcme.org
PH94B
units) (t=2.02, p=0.047) (Table 1, Figure 2). During anticipa-tion of social interaction, the improvement from visit 2 to 3for the PH94B group (17.2 subjective anxiety units) did notdiffer significantly from that of the placebo group (12.2subjective anxiety units) (Table 1, Figure 3).There were no significant differences between groups in
change in Liebowitz Social Anxiety Scale score from visit 1(mean=94.6, SD=18.3) to visit 4 (mean=86.8, SD=21.4).
Sensitivity
A sensitivity analysis on the primary outcome measureswas conducted to assess the influence of the seven par-ticipants who were excluded from the final efficacy analyses.
The overall trend of all the tests remained the same whenthe excluded participants were included in the analysis.DifferencesbetweenPH94Bandplacebo treatment remainedstrong for the public speaking challenge (p=0.01) and theCGI improvement score (p=0.001), although the changefor the social interaction challenge fell short of significance(p=0.054).
Safety and Tolerability
Participants were asked about adverse events at eachvisit. Mild or moderate adverse events were infrequent anddid not differ significantly between the PH94B and placebogroups (Table 2). Headache and gastrointestinal discomfort
TABLE 1. Subjective Units of Distress Scores for Women With Social Anxiety Disorder Receiving Intranasal Aerosol PH94B orPlacebo Before and During Public Speaking and Social Interaction Challenges
Visit 2a (Baseline) Visit 3 (Treatment)
PH94B Group (N=45) Placebo Group (N=46) PH94B Group (N=45) Placebo Group (N=46)
Challenge and Phase Mean SD Mean SD Mean SD Mean SD
Public speakingResting 54.89 29.3 55.22 23.2 46.22 28.1 50.22 29.1Anticipation 61.03 24.9 66.03 23.1 47.72 26.2 60.87 26.1Performance 79.23 13.2 80.69 13.7 52.55 22.9 66.68 19.1
Social interactionResting 45.60 27.5 49.78 29.6 33.33 24.0 39.22 28.2Anticipation 51.22 26.7 52.45 29.0 34.02 23.4 40.20 26.3Performance 52.79 26.3 54.16 27.4 34.54 24.2 47.58 24.4
a At visit 2, both groups received placebo.
FIGURE 2. Public Speaking Challenge, Minute-by-Minute Subjective Units of Distress Scores for Women With Social AnxietyDisorder Receiving Intranasal Aerosol PH94B (N=45) or Placebo (N=46)a
a At visit 2, both groups received placebo. R=resting.
Am J Psychiatry 171:6, June 2014 ajp.psychiatryonline.org 679
LIEBOWITZ, SALMAN, NICOLINI, ET AL.
Liebowitz MR et al., 2014 Am J Psych
![Page 36: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/36.jpg)
www.mghcme.org
Inositol Monophosphate Inhibitor
• Ebselen (SPI-1005)• “Lithium mimetic”• Fast Track Status in Meniere’s Disease.• Phase II study in bipolar disorder.
![Page 37: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/37.jpg)
www.mghcme.org
Neuromodulation
Henry et al., J. ECT 2001
![Page 38: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/38.jpg)
www.mghcme.org
Neuromodulation
• Deep TMS• TMS: Theta burst
- 5 RCT’s, 221 subjects- pooled RR 35.6% v 17.5% p=0.005 Berlim MT et al. , 2017.
• ECT- Multifocal Stimulation• Magnetic Seizure and iLAST Therapy
![Page 39: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/39.jpg)
www.mghcme.org
Botox
• Corrugator and Procerus muscles injections• Facial nerve signaling would shift. • Phase II trial results were mixed. • Postmarketing safety surveillance: Botox
cohorts reported fewer depressive AE’s.
Markunts T et al., Sci Rep. July, 2020
![Page 40: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/40.jpg)
www.mghcme.org
Physiotherapeutic Facial Massage
• 15 Minutes daily• Relaxation of facial muscles associated with
negative emotion.• Strengthening of facial muscles associated
with positive emotion.• Study completion date June, 2021.
![Page 41: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/41.jpg)
www.mghcme.org
Adjunct Tools
• Teen Depression Module: online tool for PCP’s to screen teens for Depression
• CBT augmented with text messaging: Individual and Group
• Depression Decision Aid (DDA) – Shared decision making tool. -Improved treatment initiation but not outcome.
![Page 42: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/42.jpg)
www.mghcme.org
Genotyping
PK: • Cytochrome P450 IsoenzymesPD: • SERT (S)• Antidepressant transport• Individual Receptors -5-HT1A; 5-HT-2A• BDNF – Val 66Met – decreased hippocampal volume• IL-1b - mRNA levels higher in non-responders. • IL-6 (rs 7801617) – escitalopram response. • Polygenic Risk Scores
![Page 43: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/43.jpg)
www.mghcme.org
Genotyping
FDA: October 31, 2018: • “… the relationship between DNA variations and
the effectiveness of antidepressant medications has never been established.”
• “There are a limited number of cases for which at least some evidence does exist to support a correlation between a genetic variant and drug levels within the body, and this is described in the labeling of FDA cleared approved genetic test and FDA approved medications.”
![Page 44: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/44.jpg)
www.mghcme.org
Conclusions
• Glutamate system offers multiple targets. Avoiding the psychotomimetic effect while maintaining efficacy is the challenge.
• Addiction and fatalities from OD have slowed progress on opiates and hallucinogens.
• Metabolic consequences of illness/medications suggests some acute treatments may worsen long-term course of illness.
• Rational Polypharmacy?
![Page 45: Novel Treatments for Mood Disorders · 2020. 10. 9. · Psych. Allosteric Modulators of NMDA •Positive-CAD-9303 –negative sx’sof Schizophrenia •Negative-CAD-9271-Treatment](https://reader033.fdocuments.in/reader033/viewer/2022053123/60ac556be40fae61d044aad2/html5/thumbnails/45.jpg)
www.mghcme.org
References
1. Individual Company websites.2. Clinical trials.gov3. FDA.gov4. Wikipedia; 9/23/2018 List of Investigational Antidepressants.5. Mental Health Daily; 30+ New Antidepressants (2018): Drugs
in Clinical Trials.